Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation
Open Access
- 14 August 2020
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 192 (3), 425-432
- https://doi.org/10.1111/bjh.17041
Abstract
Haemolytic disease of the fetus and newborn (HDFN) remains an important cause of fetal mortality with potential neonatal and longer‐term morbidity. HDFN is caused by maternal red cell alloimmunisation, with IgG antibodies crossing the placenta to destroy fetal erythroid cells expressing the involved antigen. Intrauterine fetal blood transfusion is the therapy of choice for severe fetal anaemia. Despite a strong evidence base and technical advances, invasive fetal therapy carries risk of miscarriage and preterm birth. Procedure‐related risks are increased when invasive, in utero transfusion is instituted prior to 22 weeks to treat severe early‐onset fetal anaemia. This review focuses upon this cohort of HDFN and discusses intravenous immunoglobin (IVIg) and novel monoclonal antibody (M281, nipocalimab) treatments which, if started at the end of the first trimester, may attenuate the transplacental passage and fetal effects of IgG antibodies. Such therapy has the ability to improve fetal survival in this severe presentation of HDFN when early in utero transfusion may be required and may have wider implications for the perinatal management in general.This publication has 80 references indexed in Scilit:
- The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapiesJCI Insight, 2011
- IgG Placental Transfer in Healthy and Pathological PregnanciesJournal of Immunology Research, 2011
- 444: Routine urine dipsticks not necessary at every prenatal visitAmerican Journal of Obstetrics and Gynecology, 2007
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunizationAmerican Journal of Obstetrics and Gynecology, 2007
- The antiinflammatory activity of IgG: the intravenous IgG paradoxThe Journal of Experimental Medicine, 2007
- An Audit of Outcome in Intravascular Transfusions Using the Intrahepatic Portion of the Fetal Umbilical Vein Compared to CordocentesisFetal Diagnosis and Therapy, 2006
- The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopeniaAmerican Journal of Obstetrics and Gynecology, 2005
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOODThe Lancet, 1981
- Intrauterine Transfusion of Foetus in Haemolytic DiseaseBMJ, 1963